![Bertil Lindmark](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Bertil Lindmark
Direktor/Vorstandsmitglied bei
ALK-ABELLÓ A/S
Vermögen: 39 057 $ am 30.06.2026
Profil
Bertil E.
Lindmark is currently Chairman of the Board at Aqilion AB since 2022.
Holds director positions at Aslan Pharmaceuticals (Shanghai) Co. Ltd., Cellevate AB since 2019, and ALK-Abello A since 2021.
Serves as Venture Partner at Xgen Venture Sgr SpA since 2023 and Professor-Emeritus at the University of Gothenburg.
Formerly Director at Medicon Valley Alliance FMBA. Executive Director and Executive Director-R&D at Almirall SA from 2011 to 2015.
Chief Scientific & Medical Officer at ASLAN Pharmaceuticals Pte Ltd. from 2015 to 2019.
Vice President at AstraZeneca Pharma India Ltd. from 1991 to 2009.
Chief Medical Officer at eTheRNA immunotherapies NV from 2018 to 2020 and at Damora Therapeutics, Inc. from 2020 to 2023.
Head-Clinical Development at AstraZeneca Japan Ltd. from 2009 to 2015.
Listed as Chief Medical Officer at Vicore Pharma Holding AB from 2024 to 2026.
Earned a doctorate from the University of Lund in 1991.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VICORE PHARMA HOLDING AB 0,01 % | 31.12.2025 | 30 000 ( 0,01 % ) | 39 057 $ | 30.06.2026 |
Aktive Positionen von Bertil Lindmark
| Unternehmen | Position | Beginn |
|---|---|---|
| ALK-ABELLÓ A/S | Direktor/Vorstandsmitglied | 18.03.2021 |
Aslan Pharmaceuticals (Shanghai) Co. Ltd. | Direktor/Vorstandsmitglied | - |
Cellevate AB
 Cellevate AB BiotechnologyHealth Technology Develops cell culture products for gene therapy and provides novel vaccines biomanufacturing services | Direktor/Vorstandsmitglied | 01.02.2019 |
Xgen Venture Sgr SpA
 Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 01.01.2023 |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is an active manager which invests companies located in Sweden. The firm follows of life science companies. It provides financing for early-stage capital requirements. | Vorsitzender | 01.08.2022 |
University of Gothenburg
 University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Bertil Lindmark
| Unternehmen | Position | Ende |
|---|---|---|
| VICORE PHARMA HOLDING AB | Technik-/Wissenschafts-/F&E-Leiter | 05.03.2026 |
| DAMORA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.10.2023 |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2020 |
| ░░░░░ ░░░░░░░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Bertil Lindmark
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
70
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Almirall SA
 Almirall SA Pharmaceuticals: MajorHealth Technology Engages in the development, manufacture and sale of pharmaceuticals | Health Technology |
ALK-Abello A/S
 ALK-Abello A/S Pharmaceuticals: MajorHealth Technology Develops and produces, markets products for diagnosing, treating allergies, allergic asthma & acute anaphylactic reactions | Health Technology |
AstraZeneca Pharma India Ltd.
 AstraZeneca Pharma India Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
University of Lund
 University of Lund Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Gothenburg
University of Gothenburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aqilion AB
Aqilion AB Investment ManagersFinance Aqilion AB is an active manager which invests companies located in Sweden. The firm follows of life science companies. It provides financing for early-stage capital requirements. | Finance |
Astrazeneca Japan Ltd.
 Astrazeneca Japan Ltd. Medical/Nursing ServicesHealth Services Provides healthcare services | Health Services |
Medicon Valley Alliance FMBA
 Medicon Valley Alliance FMBA Miscellaneous Commercial ServicesCommercial Services Operates Danish-Swedish life science cluster Medicon Valley | Commercial Services |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
ASLAN Pharmaceuticals Pte Ltd.
 ASLAN Pharmaceuticals Pte Ltd. BiotechnologyHealth Technology Develops novel medicines for global markets | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Aslan Pharmaceuticals (Shanghai) Co. Ltd. | |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
Cellevate AB
Cellevate AB BiotechnologyHealth Technology Develops cell culture products for gene therapy and provides novel vaccines biomanufacturing services | Health Technology |
Xgen Venture Sgr SpA
Xgen Venture Sgr SpA Investment ManagersFinance XGEN Venture invests in companies located in Italy. The firm focuses on the life science sectors. It participates in early stage capital transactions. | Finance |
